Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2013 May;57(5):2365-8.
doi: 10.1128/AAC.02288-12. Epub 2013 Feb 12.

Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model

Affiliations

Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model

Sona Kucharíková et al. Antimicrob Agents Chemother. 2013 May.

Abstract

This study addresses the effects of micafungin, caspofungin, and anidulafungin against Candida albicans biofilms developed in a subcutaneous catheter rat model system. Doses of 5, 10, and 30 mg/kg (of body weight)/day (the last only for micafungin) were given intravenously for 5, 7, and 10 days. All three echinocandins caused a significant reduction of the Candida cell numbers on the implanted catheters and are thus promising for the treatment of biofilm-related infections.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Effects of systemic administration of micafungin (MFG), caspofungin (CSP), and anidulafungin (AND) on mature Candida albicans biofilms developed in a subcutaneous rat model. Animals were treated with two different doses of each drug, 5 mg/kg (A) and 10 mg/kg (B), for 5, 7, or 10 days. Open circles represent the log10 numbers of CFU of C. albicans cells retrieved from each catheter. The horizontal lines indicate the median values for log10 numbers of CFU obtained per catheter. Differences between the echinocandin-treated group and the control (C) group were considered statistically significant at P values of ≤0.05 (*) and ≤0.01 (**).

Similar articles

Cited by

References

    1. Pappas PG, Kauffman CA, Andes D, Benjamin DK, Jr, Calandra TF, Edwards JE, Jr, Filler SG, Fisher JF, Kullberg BJ, Ostrosky-Zeichner L, Reboli AC, Rex JH, Walsh TJ, Sobel JD. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503–535 - PMC - PubMed
    1. Kuhn DM, George T, Chandra J, Mukherjee PK, Ghannoum MA. 2002. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. 46:1773–1780 - PMC - PubMed
    1. Bachmann SP, VandeWalle K, Ramage G, Patterson TF, Wickes BL, Graybill JR, López-Ribot JL. 2002. In vitro activity of echinocandins against Candida albicans biofilms. Antimicrob. Agents Chemother. 46:3591–3596 - PMC - PubMed
    1. Shuford JA, Rouse MS, Piper KE, Steckelberg JM, Patel R. 2006. Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model. J. Infect. Dis. 194:710–713 - PubMed
    1. Lazzell AL, Chaturvedi AK, Pierce CG, Prasad D, Uppuluri P, Lopez-Ribot JL. 2009. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J. Antimicrob. Chemother. 64:567–570 - PubMed

Publication types